(PRWEB) September 24, 2004
E Med Future, Inc. (OTCBB:EMDF - News) announced that the company has signed a licensing and distribution agreement with IT Development Solutions, Inc. (IDS) http://www.ids-worldwide.com, to exclusively manufacture, distribute and sell NeedleZapÂ® in Pakistan and the United Arab Emirates (UAE), said Robert Ochsendorf, president.
"Our recent announcements involving China, Australia, Mexico, Uganda and now Pakistan and UAE help demonstrate our ongoing efforts to introduce NeedleZapÂ® to markets worldwide," said Ochsendorf. "We're excited to have IDS as a partner in the fight against the spread of infectious diseases through contaminated needles and accidental needlesticks."
IDS has already completed construction of a new high-tech manufacturing facility that will reduce the cost of producing NeedleZapÂ® by roughly 60 percent. According to Ochsendorf, for each 100,000 units sold, E Med will make an additional $1.5 million gross profit. The units manufactured in Pakistan will only be sold outside the United States. IDS completed this construction at its own expense, retaining a staff with more than 15 years of experience in ABS plastic manufacturing procedures.
IDS is adding the E Med product line to its significant distribution affiliates in the Asian and Gulf Regions. In the past, IDS has established exclusive distribution and sales contracts for various companies in Pakistan and the UAE.
As part of the agreement, E Med will engage IDS President Patrick Downs as a consultant for a two-year period. Mr. Downs will provide advice and assistance with respect to the production of NeedleZapÂ® at the new manufacturing facility.
For more information, call 877-855-1319 or visit http://www.needlezap.com.
Statements that describe E Med Future's future plans, objectives or goals are forward-looking statements. These forward-looking statements can generally be identified as such because the context of the statement will include words such as E Med "expects," "anticipates" or words of similar import. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of E Med, as appropriate, and market valuations of their stock, which could cause actual results to differ materially from those currently anticipated. Please refer to E Med's 10-K, 10-Qs and other filings with the SEC for a description of other factors that could cause actual results to differ from those anticipated.
For more information contact:
Bill Scott Vice President Business Development
# # #